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Abstract
Aims: To validate the clusters of Swedish individuals with recent-onset diabetes at
differential risk of complications, which were identified in a previous study, in three
global populations with long-standing type 2 diabetes (T2D) who were at high cardio-
vascular risk, and to test for differences in the risk of major diabetes complications
and survival endpoints.
Materials and methods: We assigned participants from recent global outcomes trials
(DEVOTE [n = 7637], LEADER [n = 9340] and SUSTAIN-6 [n = 3297]) to the previ-
ously defined clusters according to age at diabetes diagnosis, baseline glycated
haemoglobin (HbA1c) and body mass index (BMI). Outcomes were assessed using
Kaplan–Meier analysis and log-rank tests.
Results: The T2D clusters were consistently replicated across the three trial cohorts.
The risk of major adverse cardiovascular events and cardiovascular death differed sig-
nificantly, in all trials, across clusters over a median follow-up duration of 2.0, 3.8 and
2.1 years, respectively, and was highest for the cluster of participants with high
HbA1c and low BMI (P < 0.05 in DEVOTE and LEADER). In LEADER and SUSTAIN-6,
the risk of nephropathy differed across clusters (P < 0.0001 and P = 0.003, respec-
tively). The risk of severe hypoglycaemia differed in DEVOTE (P = 0.006).
Conclusions: Previously identified clusters can be replicated in three geographically
diverse cohorts of long-standing T2D and are associated with cluster-specific risk
profiles for additional clinical and survival outcomes, providing further validation of
the clustering methodology. The external validity and stability of clusters across
cohorts provides a premise for future work to optimize the clustering approach to
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yield T2D subgroups with maximum predictive validity who may benefit from
subtype-specific treatment paradigms.
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2 diabetes
1 | INTRODUCTION
Type 2 diabetes (T2D) remains a major challenge to the health of a
large and rapidly increasing part of the global population.1 Despite the
availability of a range of pharmacological treatments, a sizeable pro-
portion of affected individuals develop severe and potentially fatal
complications, including cardiovascular disease, renal disease and
hypoglycaemia.2–4 Considering the marked heterogeneity of the dis-
ease in terms of its clinical presentation, multifactorial risk factors and
diverse outcomes and disease course, characterizing distinct sub-
groups of individuals with T2D may allow a more targeted and individ-
ualized therapeutic approach to improve patient outcomes and
decrease costs.5,6
Recently, Ahlqvist et al7 identified five clinically relevant and dis-
tinct phenotypic clusters in a large cohort of Swedish individuals with
adult-onset diabetes (the All New Diabetes in Scania [ANDIS] cohort,
8980 individuals) using data-driven clustering based on six clinically
available and diabetes-associated variables. Four clusters resembled
T2D phenotypes and were characterized by age at diagnosis, β-cell
function and insulin resistance (represented by homeostatic model
assessment [HOMA] indices), body mass index (BMI), and glycated
haemoglobin (HbA1c). A fifth cluster was defined by autoantibodies
and resembled autoimmune type 1 diabetes. The identified subgroups
showed disparate patterns in initiation of therapies and risk of early
complications of diabetes, suggesting that these efforts to identify
homogenous subgroups within the broader patient population may
ultimately be used to improve unequal prognosis within the same dis-
ease classification.
Developing robust methodologies for identifying phenotypic T2D
clusters marks an important milestone. Validation by replicating the
clusters in additional and different diabetes cohorts, including geo-
graphically diverse populations, is needed to establish the generaliz-
ability of the clustering methodology. In the study by Ahlqvist et al,7
the ANDIS clusters were replicated accurately in two additional
cohorts, including a smaller cohort of individuals with long-standing
T2D. Additionally, Dennis et al8 successfully replicated the ANDIS
clusters in the T2D populations of the ADOPT and RECORD clinical
trials with focus on glycaemia-related and renal outcomes. Moreover,
clustering was recently attempted in a cohort of individuals with type
1 diabetes or T2D from Germany.9 To date, however, no study has
investigated how the clustering approaches perform and aid in the
prediction of long-term diabetes-related complications that account
for the major morbidity and mortality of the disease, including cardio-
vascular risk and iatrogenic outcomes such as severe hypoglycaemia,
in cohorts of individuals with advanced T2D and high risk of associ-
ated comorbidities. These validation studies are needed to establish
fundamentally the merit of a compiled clustering approach, prior to
further work characterizing and refining the resulting T2D clusters for
optimal clinical utility. Accordingly, to validate and test the applicabil-
ity of the ANDIS clustering approach in geographically diverse cohorts
of individuals with advanced diabetes and high cardiovascular risk, we
aimed to identify the same distinct subgroups of participants in the
DEVOTE,10 LEADER11 and SUSTAIN-612 cardiovascular outcomes tri-
als (CVOTs). These trials provide data from controlled, global investi-
gations of a modern, long-acting basal insulin (insulin degludec)10 and
two widely prescribed subcutaneous glucagon-like peptide 1 ana-
logues (liraglutide11 and semaglutide12). Further, to test the utility of
the clusters in predicting the risk of diabetes-related outcomes, we
explored the association between the identified clusters and cardio-
vascular events (including major adverse cardiovascular events
[MACE], cardiovascular death, non-fatal stroke and heart failure), all-
cause death, new or worsening nephropathy and severe
hypoglycaemia.
2 | MATERIALS AND METHODS
2.1 | Study populations
We performed clustering analyses on baseline data from a total of
20 274 participants recently enrolled in three randomized, double-
blind, controlled, parallel-group multinational CVOTs in adults with
long-standing T2D, all treated on a background of standard of care.
The populations were enriched for cardiovascular risk, which in this
study is graded as high (at least 50 years of age and established car-
diovascular or chronic kidney disease) or medium (at least 60 years of
age and presence of specific cardiovascular risk factors). The CVOTs
formally confirmed the cardiovascular safety of insulin degludec
(DEVOTE, conducted from October 2013 to October 2016; 7637 par-
ticipants), liraglutide (LEADER, conducted from September 2010 to
December 2015; 9340 participants) and semaglutide (SUSTAIN-6,
conducted from February 2013 to March 2016; 3297 participants). In
DEVOTE, the comparator was insulin glargine U100; LEADER and
SUSTAIN-6 were placebo-controlled. Participants with available infor-
mation on the selected clustering variables (see below) were included
in the analyses.
Across the trials, more than 80% of the enrolled participants were
classified as having high cardiovascular risk, the mean age was
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64 years or older and the mean duration of diabetes was 12 years or
longer. The mean HbA1c level was 8.4% in DEVOTE and 8.7% in both
LEADER and SUSTAIN-6. The median follow-up time was 2.0, 3.8 and
2.1 years in DEVOTE, LEADER and SUSTAIN-6, respectively. Addi-
tional details are available in the original publications.10–12
2.2 | Cluster validation
We adopted the clustering methodology used by Ahlqvist et al7; how-
ever, the presence of glutamic acid decarboxylase antibodies (GADA),
which was used to identify and classify individuals with autoimmune
type 1 diabetes as severe autoimmune diabetes (cluster 1), was not
available in our T2D-only cohorts. Moreover, we did not include
HOMA indices because, in contrast to the ANDIS cohort, our cohorts
included a high number of individuals treated with insulin; this may
confound the interpretation of the indices, which were based on insu-
lin measurements. Thus, our clustering was based on HbA1c level and
BMI at baseline (defined as trial entry), and age at T2D diagnosis.
Rather than a de novo clustering analysis, we performed a validation
study of the T2D clusters from the ANDIS cohort. In the clustering pro-
cess, the three variables for each participant were first scaled and
centred. Second, participants were assigned to one of four clusters
based on the smallest Euclidean distance to the same cluster centres
identified by Ahlqvist et al7 (nearest centroid). To fully evaluate the
accuracy of the clustering in our cohorts, we computed the subject-
specific ratio between the smallest and the second smallest Euclidian
distance to the ANDIS cluster centres; a ratio close to zero indicates a
low distance to a cluster and therefore a strong participant-cluster asso-
ciation, whereas a ratio close to 1 indicates a weak association.
Acknowledging the cohort differences between the present study and
the study by Ahlqvist et al,7 we chose letter-based cluster labels, which
correspond to the replicated ANDIS labels as follows: Cluster A, severe
insulin-deficient diabetes (ANDIS cluster 2); Cluster B, severe insulin-
resistant diabetes (cluster 3); Cluster C, mild obesity-related diabetes
(cluster 4); and Cluster D, mild age-related diabetes (cluster 5).
2.3 | Associations of clusters and outcomes
We assessed the following outcomes by cluster for each of the three
trials separately: three-component MACE (primary outcome in all three
CVOTs; components were the first occurrence of cardiovascular death,
non-fatal myocardial infarction or non-fatal stroke); cardiovascular
death separately; all-cause death; heart failure requiring hospitalization;
severe hypoglycaemia (hypoglycaemic episodes classified as severe
according to contemporary American Diabetes Association [ADA] defi-
nitions13); and new or worsening nephropathy for LEADER and
SUSTAIN-6 (composite of new-onset persistent macroalbuminuria, per-
sistent doubling of the serum creatinine level, end-stage renal disease
or death attributable to renal disease). The outcomes had been con-
firmed by adjudication performed by an external, independent commit-
tee in a blinded manner.
For each outcome, the risk was assessed using Cox regression
and Kaplan–Meier analysis. Associations between clusters and out-
come events were evaluated using a log-rank test. All analyses were
performed using R (version 3.5.1).14
3 | RESULTS
3.1 | Cluster characteristics
Using three T2D-related participant characteristics (HbA1c and BMI
at baseline, and age at T2D diagnosis), participants in the DEVOTE,
LEADER and SUSTAIN-6 populations were assigned to four distinct
clusters (Clusters A to D; Figure 1) mapped to the ANDIS parameters.
Across the three populations (Table 1), a noticeably worse degree of
glycaemic control characterized Cluster A (mean HbA1c at baseline
10.9% to 11.1% compared with ~ 7.7% to 8.5% in the other three
clusters). Clusters B and C were characterized by greater baseline BMI
(~ 37–39 vs. ~ 28–30 kg/m2 in the other two clusters) and the age of
T2D diagnosis in Clusters B and D clusters (~ 53–56 years) were
higher than in the other clusters and consistently lowest in Cluster C
(~ 37–41 years). The number of participants in each cluster was very
similar across the three trial populations; more than one-third of the
participants was assigned to Cluster D, a quarter was assigned to
Cluster B and around one-fifth was assigned to each of Clusters A and
C. The sex distribution did not differ markedly across the clusters. Fur-
ther, Cluster C was characterized by many participants with long-
standing (>10 years) T2D. For LEADER and SUSTAIN-6, Clusters B
and D were defined by a higher prevalence of insulin-naïve individ-
uals, whereas for DEVOTE, all clusters had a low prevalence of such
individuals. The prevalence of participants at high cardiovascular risk
(as compared to participants with medium cardiovascular risk) was
higher in Cluster C than in the other clusters (~ 88%–90% vs. ~ 79%–
84% of the participants), whereas there did not appear to be a consis-
tent difference in renal function across clusters in any of the trials.
3.2 | Risk–cluster association
We evaluated the risk of multiple outcomes in the three trials
(Figures 2 and 3, and Table 2). Overall, cardiovascular event risk dif-
fered across clusters, as evident from the clear and early separation of
the cumulative incidence curves. Specifically, the risk of MACE and
cardiovascular death was highest in Cluster A in all three trials; the dif-
ferences were statistically significant in DEVOTE and LEADER
(P = 0.026 and P < 0.0001, respectively). The risk of all-cause death in
LEADER was greatest in Cluster A (P < 0.001). The risk of heart failure
(Table S1) also differed across clusters (P < 0.006), most prominently
in SUSTAIN-6, where the risk was markedly greater for Cluster C
compared to the other clusters (P = 0.006). For both LEADER and
SUSTAIN-6, the risk of new or worsening nephropathy differed across
clusters (P < 0.0001 and P = 0.003, respectively). In DEVOTE only, the
risk of severe hypoglycaemia differed across the clusters (P = 0.006).
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3.3 | Clustering performance
The performance of the clustering was assessed by the ratio between
the smallest and the second smallest Euclidian distance to the cluster
centres (Figure S1), where a smaller distance ratio indicates a more
unique participant-to-cluster association. Considering the somewhat
large number of participants with a relatively high distance ratio, out-
comes were reassessed when excluding data for participants with a
distance ratio greater than 0.8 (ie, those most difficult to assign to a
single cluster). In these sensitivity analyses (Figures S2 and S3 [dashed
lines] and Table S1), the risk–cluster associations and the associated
statistical significances were consistent with those of the original ana-
lyses with a single exception: in the sensitivity analysis, the risk for
nephropathy in SUSTAIN-6 did not statistically significantly differ
across clusters.
4 | DISCUSSION
In the present study, we applied recent phenotypic clustering
approaches7 to three populations of individuals with T2D enriched for
high cardiovascular and/or renal risk who were enrolled in controlled
CVOTs (DEVOTE,10 LEADER11 and SUSTAIN-612), based on a subset
of readily available clinical measures obtained before exposure to trial
treatment. The main aim was to provide additional external and broad
validation of the methodology originally developed by Ahlqvist et al.7
Our cohorts were geographically more diverse and characterized by
more advanced diabetes compared with the cohorts of the previous
studies using the methodology (ie, the ANDIS cohort and cohorts
from the follow-on studies8,9). We demonstrate similar results to
those obtained with the six-variable clustering approach in the ANDIS
study by clustering based on three variables, which should be clinically
available in all individuals with T2D. As an additional novel aspect, we
showed that the approaches can be used to differentiate the risk of
diabetes outcomes in global T2D populations.
The validity of the ANDIS clustering approach was confirmed by
our findings. Despite the different cohorts and the longer duration of
the follow-up in the outcome trials, the distribution of trial partici-
pants across the corresponding clusters generally align between the
ANDIS cohort and our cohorts. While differences across the studied
cohorts between the ANDIS study and our investigation preclude a
direct comparison of the identified risks, there appeared to be a gen-
eral alignment between the risk of cardiovascular and renal disease
across clusters in DEVOTE, LEADER and SUSTAIN-6 and the risk of
early complications (Clusters A and B), as shown for the ANDIS clus-
ter. An interesting finding of the study was that Cluster A, the
insulinopenic subgroup defined by high HbA1c and low BMI, showed
the highest incidence of cardiovascular events, even though long-term
insulin resistance and hyperinsulinaemia are known cardiovascular risk
factors. It is possible that these results are attributable to the differ-
ences between the study populations, where the insulinopenic group
from the trials (Cluster A) may not have exhibited the degree of insulin
deficiency of the severe insulin-deficient diabetes cluster in the
Ahlqvist et al cohort. In addition, HbA1c was appreciably higher in
Cluster A compared with the other clusters across all study
populations (~ 11% in Cluster A, compared with <8.5% in the other
subgroups), which may have accelerated cardiovascular risk through
F IGURE 1 Clustering parameters (glycated haemoglobin and
body mass index at baseline, and age at diabetes diagnosis) by cluster
assignment in the DEVOTE, LEADER and SUSTAIN-6 trials. Boxes are
the median, and 25th and 75th percentiles; whiskers are the 1st and
99th percentiles. Values outside these percentiles are represented by
open circles. Cluster labels correspond to the ANDIS labels as follows:
Cluster A, severe insulin-deficient diabetes; Cluster B, severe insulin-
resistant diabetes; Cluster C, mild obesity-related diabetes; and
Cluster D, mild age-related diabetes. Baseline was defined as trial
entry
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mechanisms not directly mediated by insulin resistance or
hyperinsulinaemia.
In the present study, we also evaluated the risk of severe
hypoglycaemia, relevant primarily for persons treated with an insulin.
As evident from the early and clear separation of the incidence curves
(Figure 3), the risk of severe hypoglycaemia differed between clusters
in DEVOTE where all participants were treated with insulin, probably
reflecting the low incidence of severe hypoglycaemic episodes in
LEADER and SUSTAIN-6. In DEVOTE, the risk of severe
hypoglycaemia was greatest in Cluster C. This was also observed for
LEADER, but the differences were not statistically significant. For
DEVOTE, the observation may relate to the lower prevalence of
insulin-naïve individuals in this cluster and to the fact that DEVOTE
(but not LEADER and SUSTAIN-6) was a treat-to-target trial, which
required sufficiently high doses of basal insulin to achieve the
prespecified HbA1c target.
The generalizability of risk stratification shown in the present
study should be considered in the context of the fact that the results
were observed for individuals participating in controlled clinical trials.
Moreover, in real-world clinical settings, competing risks may have a
greater influence than in relatively short-term clinical trials. Thus,
while we demonstrate that it is possible to associate the validated
clusters with selected unique risk patterns, further investigations are
needed to fully establish the legitimacy of these findings and their
clinical applicability.
Ahlqvist et al elucidated single nucleotide polymorphisms as asso-
ciated with the clusters7; currently, however, the broad clinical appli-
cability of genotypic clustering is low. Conversely, T2D subgroups
may be more easily applied in clinical practice if they rely on fewer
variables while maintaining accuracy and predictive validity for other
long-term outcomes. In this context, we were able to replicate the
ANDIS clusters based on three variables compared with the five rele-
vant for T2D in the original work by Ahlqvist et al.7 In particular, the
GADA variable was disregarded in our analyses, because all three
cohorts comprised patients with T2D exclusively. Moreover, this vari-
able was suspected to be of limited utility as the prevalence of GADA
is likely to be lower among the included patients with long-standing
diabetes compared with the ANDIS cohort with recent-onset diabe-
tes. Similarly, HOMA estimations of insulin resistance were discarded
because of their limited utility; interpretation is not straightforward
among a population with long-standing diabetes lacking universal
insulin naivety.
This carries important implications for the scalability and clinical
utility of clustering-based approaches in patient stratification, because
the C-peptide or insulin measurements required for the HOMA vari-
ables used in the study by Ahlqvist et al7 have not been fully stan-
dardized or recommended in general clinical practice. Thus, while the
HOMA indices may be more available clinically in the future and
acknowledging their relevance to the pathophysiology of diabetes,
our results suggest that the clustering approaches can provide ade-
quately robust and clinically useful patient stratification without those
variables. Future studies may help to elucidate if there are other clini-
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F IGURE 2 Cumulative risk of a major adverse cardiovascular event (MACE), cardiovascular (CV) death and all-cause death by cluster in the
DEVOTE, LEADER and SUSTAIN-6 trials. First occurrence of a MACE was the three-component primary outcome in each trial; components
comprised CV death, non-fatal myocardial infarction and non-fatal stroke. All outcomes had been confirmed by adjudication performed by
external, independent medical experts. Full lines represent analyses based on all eligible participants; dashed lines represent analyses based on all
except the 20% of the participants who were most difficult to assign to a single cluster (see text). P values are from a log-rank test for the analysis
of all participants. Participants at risk, shown in the tables, are for the full analysis. The median follow-up time was 2.0, 3.8 and 2.1 years in
DEVOTE, LEADER and SUSTAIN-6 respectively. N, number of participants; %, proportion of participants
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readily available in clinical settings to help further distinguish diabetes
subtypes.
The advances made by Ahlqvist et al7 represented an important
early step in identifying clusters of apparent clinical relevance and
implicated a series of key scientific steps by which the computational
clustering approach can be systematically validated, optimized and
ultimately translated to the clinical care of patients with T2D. The
generation of evidence supporting the scalability and stability of the
computational clustering approach across different populations of
patients with T2D represents the first step in this workflow. After
careful external validation, there remain important research questions
that warrant thorough investigation before the T2D clusters can be
translated to daily clinical practice. Thus, we propose that the present
study is the first of multiple steps towards moving the T2D clusters to
the clinic and that the findings provide a premise for future studies to
test specifically how clusters can be refined via integration of different
variables to optimize cardiovascular outcome prediction beyond exis-
ting tools and dictate treatment response.
A key endeavour, for example, will be to identify additional clus-
tering variables for improved risk prediction. Early work in this area by
Dennis et al8 showed that using prognostic markers such as glomeru-
lar filtration rate and age at diagnosis alone could outperform cluster-
ing in stratifying high-risk individuals for diabetic nephropathy
outcomes. As this was an external validation study, we did not per-
form a de novo clustering analysis and instead used the cluster centres
from the previous study of interest in order to test whether previously
identified clusters were stable in our cohort; therefore, including novel
variables in this analysis was not feasible given the constraints of the
F IGURE 3 Cumulative risk of severe hypoglycaemia and new or worsening of nephropathy by cluster in the DEVOTE, LEADER and
SUSTAIN-6 trials. New or worsening of nephropathy was defined as occurrence of one of the following: new onset of persistent
macroalbuminuria or doubling of the serum creatine concentration or of creatine clearance; continuous renal replacement therapy; death
attributable to renal disease. Hypoglycaemic episodes were classified as severe according to contemporaneous American Diabetes Association
criteria. All outcomes had been confirmed by adjudication performed by external, independent medical experts. Full lines represent analyses
based on all eligible participants; dashed lines represent analyses based on all except the 20% of the participants who were most difficult to
assign to a single cluster (see text). P values are from a log-rank test for the analysis of all participants. Participants at risk, shown in the tables, are
for the full analysis. The median follow-up time was 2.0, 3.8 and 2.1 years in DEVOTE, LEADER and SUSTAIN-6, respectively. N, number of
participants; %, proportion of participants
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validation methods. It is likely, however, that the integration of addi-
tional risk-associated and easy-to-measure biomarkers could improve
risk stratification; the predictive performance of the resulting T2D
subgroups should then be compared against existing cardiovascular
risk engines and other such prediction algorithms to demonstrate
proof of enhanced, population-specific estimations.
In addition, current treatment guidelines (eg, the ADA/European
Association for the Study of Diabetes consensus report15) focus on
risk prevention that is individualized to patient priorities (eg, reducing
cardiorenal risk, hypoglycaemia risk, body weight or the cost of ther-
apy). However, data to guide the individualization of diabetes therapy
is currently lacking. Accordingly, a more in-depth and precise under-
standing of diabetes subtypes is central for efforts to achieve the
promise of precision medicine in this complex disease to benefit indi-
viduals with diabetes as well as the healthcare system. Foremost, it
remains unclear if the subgroups are useful beyond risk stratification,
specifically, how such groups may receive and respond to various
therapies. Maximally useful subtypes should capture heterogeneity
that describes not only who is at risk, but also, within risk strata, for
whom a given therapy is likely to be associated with meaningful bene-
fit. To this end, there is a need to establish whether treatment
responses to different drug classes differ across diabetes subtypes.
As the field evolves to explore how phenotypic clusters of
patients with T2D can be refined and optimized, there may be multi-
ple opportunities to guide treatment decisions. Algorithms allowing
the clinician to base decisions regarding new or adjusted therapy
choices on cluster-based predictions and prognoses could become rel-
evant. For example, one application of cluster-specific T2D therapy
could be to first use a few clinical measurements to assign a newly
diagnosed individual to a well-established phenotypic cluster with a
preferred treatment regimen. Second, longitudinal outcome follow-up
after selected time points comparing predicted and actual outcomes
could provide information for the clinician to accurately adjust the
drug class, posology or co-medication to further optimize the long-
term outcomes for people with diabetes. Our results suggest that
well-established cardiovascular, renal and hypoglycaemia-related out-
comes may be relevant to follow and adjust treatment based on
response. More specifically, our findings suggested that careful
prospective attention to cardiovascular risk is especially warranted
for Cluster A (characterized by Ahlqvist et al as severe insulin-
deficient diabetes7), which appears to be associated with signifi-
cantly higher risk of MACE compared with individuals in the other
clusters. However, these outcomes are probably not all equally rel-
evant for every subgroup of individuals with T2D, considering that
the trial populations used in the present evaluation were all
enriched for cardiovascular risk and characterized by long-standing
diabetes. Evaluation of disease-specific complications and all rele-
vant outcomes, such as diabetic retinopathy, may also help to
guide medical management of subgroups. Finally, the clusters may
be refined to incorporate additional patient data, including biologi-
cal and non-biological features that are known to influence treat-
ment results, thereby generating subgroups that carry inherent
prescriptive relevance.
In conclusion, the present study supports the validity of recent
clustering approaches in deriving distinct subtypes of diabetes. The
consistency of clusters across global populations underscores that
T2D is a heterogeneous disease with different prognoses that may
require different treatment according to specific disease subtypes.
Our findings add to the promise that a subgroup-centric and risk-
based approach for the management of diabetes is feasible to help
improve patient outcomes and to further optimize the cost–benefit
balance of current and future diabetes treatment. With this evidence
of external validity and phenotypic stability, further investigations are
needed to improve the clustering approach, including exploration of
how novel data may be incorporated to improve risk prediction and
even guide cluster-specific treatment selection, thereby increasing
clinical actionability and accelerating translation to the day-to-day
clinical care of the diverse population of patients with T2D.
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